← Leaderboards
Shengdar Tsai
Massachusetts General Hospital
$7,312,012
Attributed
$9,785,572
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,785,572 · 7
By mechanism
U01$9,678,288 · 6
F32$107,284 · 1
Top collaborators
- Akshay Sharma4 shared
- Mitchell J Weiss4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- J. Keith Joung$24,183,955
- Ru-Rong Ji$16,905,704
- Jianren Mao$21,748,037
- Ryuji Morizane$4,360,469
- Ricardo Mouro Pinto$1,596,958
Others in their field
Top investigators on “Technology”
- David Heimbrook · Leidos Biomedical Research, Inc.$995,338,451
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Eric S Lander · Whitehead Institute For Biomedical Res$606,570,095
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Richard K. Wilson · Washington University$441,856,657
Research focus
TechnologyGenome EditingSafetyIn VivoGenome-WideAffectTherapeutic Genome EditingGeneticOff-Target MutationCellsGenetic DiseasesHuman GenomeGene TherapySiteHuman DiseaseSafety AssessmentGenomic MedicineProto-OncogenesPharmaceutical PreparationsSickle Cell AnemiaProtocols DocumentationFutureEngineeringManufacture
Grant awards (17)
Novel therapeutic gene editing to induce fetal hemoglobin for sickle cell disease$1,183,000
U01 · FY2025 · HL
Sensitive, unbiased, high-throughput, cellular GUIDE-seq-2 genome-wide activity assay for therapeutic genome editing INDs$479,100
U01 · FY2025 · AI · contact PI
Ultra-sensitive, unbiased, high-throughput, biochemical CHANGE-seq genome-wide activity and gRNA sequencing assays for therapeutic genome editing INDs$479,100
U01 · FY2025 · AI · contact PI
Novel therapeutic gene editing to induce fetal hemoglobin for sickle cell disease$185,000
U01 · FY2025 · HL
Novel therapeutic gene editing to induce fetal hemoglobin for sickle cell disease$1,159,340
U01 · FY2024 · HL
Ultra-sensitive, unbiased, high-throughput, biochemical CHANGE-seq genome-wide activity and gRNA sequencing assays for therapeutic genome editing INDs$479,100
U01 · FY2024 · AI · contact PI
Sensitive, unbiased, high-throughput, cellular GUIDE-seq-2 genome-wide activity assay for therapeutic genome editing INDs$479,100
U01 · FY2024 · AI · contact PI
Novel therapeutic gene editing to induce fetal hemoglobin for sickle cell disease$1,183,000
U01 · FY2023 · HL
Sensitive, unbiased, high-throughput, cellular GUIDE-seq-2 genome-wide activity assay for therapeutic genome editing INDs$479,100
U01 · FY2023 · AI · contact PI
Ultra-sensitive, unbiased, high-throughput, biochemical CHANGE-seq genome-wide activity and gRNA sequencing assays for therapeutic genome editing INDs$479,100
U01 · FY2023 · AI · contact PI
A novel human T-cell platform to define biological effects of genome editing$609,968
U01 · FY2022 · AI · contact PI
A novel human T-cell platform to define biological effects of genome editing$610,061
U01 · FY2021 · AI · contact PI
A novel human T-cell platform to define biological effects of genome editing$610,710
U01 · FY2020 · AI · contact PI
A novel human T-cell platform to define biological effects of genome editing$611,358
U01 · FY2019 · EB · contact PI
A novel human T-cell platform to define biological effects of genome editing$651,251
U01 · FY2018 · HL · contact PI
Improving the Efficiency of Gene Targeting Using TAL Effector Nucleases$55,094
F32 · FY2014 · GM · contact PI
Improving the Efficiency of Gene Targeting Using TAL Effector Nucleases$52,190
F32 · FY2013 · GM · contact PI